Suggested remit: To appraise the clinical and cost effectiveness of mirdametinib within its marketing authorisation for for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6618
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 October 2025 - 19 November 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 22 October 2025 | In progress. Scoping commenced. |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual